Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scope Of Senate Liability Bill Likely More Narrow Than HR 5 – House Staffer

This article was originally published in The Gray Sheet

Executive Summary

A medical liability reform law that does not include product liability protection language would spur more lawsuits against device manufacturers, according to Ralph Hall, Guidant general counsel

You may also be interested in...



MQSA Reauthorization Bill Expected In Coming Months, HELP Staffers Say

Compulsory physician self-assessment of diagnostic accuracy under mammography regulations could expose radiologists to increased malpractice lawsuits if the results are made public, a physician suggested to Senate legislators April 8

MQSA Reauthorization Bill Expected In Coming Months, HELP Staffers Say

Compulsory physician self-assessment of diagnostic accuracy under mammography regulations could expose radiologists to increased malpractice lawsuits if the results are made public, a physician suggested to Senate legislators April 8

Cost Of Medicare DME, Inpatient Programs On Rise, Scully Tells Appropriators

CMS should determine whether costs of "defensive medicine" resulting from the proliferation of medical malpractice lawsuits in the U.S. are increasing Medicare expenditures for beneficiaries, according to Rep. Dave Weldon (R-Fla.)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel